# (±)-Darifenacin-$d_4$

| | |
|---|---|
| **Cat. No.:** | HY-22437S |
| **CAS No.:** | 1189701-43-6 |
| **Molecular Formula:** | $C_{28}H_{26}D_4N_2O_2$ |
| **Molecular Weight:** | 430.57 |
| **Target:** | mAChR; Isotope-Labeled Compounds |
| **Pathway:** | GPCR/G Protein; Neuronal Signaling; Others |
| **Storage:** | Please store the product under the recommended conditions in the Certificate of Analysis. |




## BIOLOGICAL ACTIVITY

| | |
|---|---|
| **Description** | (±)-Darifenacin-$d_4$ is deuterium labeled (±)-Darifenacin. (±)-Darifenacin is the racemate of Darifenacin. Darifenacin is a selective M3 muscarinic receptor antagonist[1]. |
| **$IC_{50}$ & Target** | mAChR3 |
| **In Vitro** | Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].<br>MCE has not independently confirmed the accuracy of these methods. They are for reference only. |

## REFERENCES

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

[2]. Hegde SS, et al. Functional role of M2 and M3 muscarinic receptors in the urinary bladder of rats in vitro and in vivo. Br J Pharmacol, 1997, 120(8), 1409-1418.



Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA